PDS Biotechnology PDSB 深 沪
等待开盘 08-14 09:30:00 美东时间
0.2332
-0.009
-3.64%
华盛通- 最 高0.2459
- 今 开0.242
- 成交量 438.33万股
- 最 低 0.2167
- 昨 收 0.242
- 总市值 1304.10万
- 52周最高 1.55
- 市盈率 静 --
- 换手率 7.84%
- 52周最低 0.2167
- 委 比 0.00%
- 总股本 5592.18万
- 历史最高 17.85
- 量 比 0.61
- 振 幅 12.07%
- 历史最低 0.2167
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
今天 11:51
PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 14.29 percent increase over losses of $(0.21) per share from the same period last year.
08-13 21:06
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study. The STRIVE-01 study is evaluating STRO-004 in heavily pretreated patients with advanced solid tumors. What’s Driving Sutro Biopharma (S...
08-13 02:04
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer. PDS0301 Metastatic Colorectal Cancer Focus PDS Biotechnology is prioritizing its PDS0301 program, which targets...
08-12 01:49
Palatin Technologies shares are trading higher after the company reported better-than-expected Q1 EPS results.
Palatin Technologies shares are trading higher after the company reported bette...
05-14 01:42
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
PDS Biotechnology (NASDAQ:PDSB) reported first-quarter financial results on Wed...
05-13 20:26
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 38.1 percent increase over losses of $(0.21) per share from
05-13 19:01
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Why Is PDS Biotechnology Stock Gaining Wednesday?
PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.
04-16 01:14
